We are live on ! Find out more
EPZM

Epizyme, Inc

Delisted

EPZM was delisted on the 11th of August, 2022.

98 hedge funds and large institutions have $465M invested in Epizyme, Inc in 2015 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 40 increasing their positions, 26 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 26

23% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 13

3% more funds holding

Funds holding: 9598 (+3)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

28% less call options, than puts

Call options by funds: $3.79M | Put options by funds: $5.25M

44% less capital invested

Capital invested by funds: $824M → $465M (-$359M)

Holders
98
Holders Change
+3
Holders Change %
+3.16%
% of All Funds
2.74%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.11%
New
16
Increased
40
Reduced
26
Closed
13
Calls
$3.79M
Puts
$5.25M
Net Calls
-$1.47M
Net Calls Change
-$2.12M
Name Holding Trade Value Shares
Change
Change in
Stake
GTC
26
Ghost Tree Capital
New York
$1.93M -$2.02M -100,000 -40%
SFM
27
Sphera Funds Management
Israel
$1.93M +$3.03M +150,000 New
ACP
28
Acuta Capital Partners
California
$1.8M +$2.83M +140,000 New
Marshall Wace
29
Marshall Wace
United Kingdom
$1.72M +$1.69M +83,735 +168%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$1.58M -$300K -14,842 -11%
Lord, Abbett & Co
31
Lord, Abbett & Co
New Jersey
$1.55M -$4.21M -208,508 -63%
Wellington Management Group
32
Wellington Management Group
Massachusetts
$1.51M +$320K +15,880 +16%
IHM
33
Iguana Healthcare Management
New York
$1.42M +$908K +45,000 +69%
Alyeska Investment Group
34
Alyeska Investment Group
Illinois
$1.4M -$895K -44,352 -29%
BIM
35
BlackRock Investment Management
Delaware
$1.24M -$29.4K -1,455 -1%
TCIM
36
TIAA CREF Investment Management
New York
$1.24M -$70K -3,469 -3%
QI
37
QS Investors
New York
$1.22M
Principal Financial Group
38
Principal Financial Group
Iowa
$1.07M +$26.1K +1,293 +2%
Goldman Sachs
39
Goldman Sachs
New York
$1.05M -$2.57M -127,503 -61%
Charles Schwab
40
Charles Schwab
California
$999K +$87.5K +4,334 +6%
Susquehanna International Group
41
Susquehanna International Group
Pennsylvania
$861K +$1.04M +51,312 +329%
TI
42
Turner Investments
Pennsylvania
$807K
New York State Common Retirement Fund
43
New York State Common Retirement Fund
New York
$759K -$176K -8,745 -13%
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$680K -$4.04K -200 -0.4%
SIP
45
Stoneridge Investment Partners
Pennsylvania
$677K -$306K -15,162 -22%
MC
46
Muhlenkamp & Co
Pennsylvania
$673K +$10.3K +510 +1%
AllianceBernstein
47
AllianceBernstein
Tennessee
$597K +$24.8K +1,230 +3%
OPPM
48
Opus Point Partners Management
New York
$593K -$531K -26,300 -36%
GPCM
49
Granite Point Capital Management
Massachusetts
$579K
TA
50
Teachers Advisors
New York
$558K +$21.6K +1,068 +3%

EPZM Hedge Fund Activity: Q3 2015 in Review

98 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q3 2015, worth a combined $465M — down 44% from $824M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new EPZM positions and 13 closed out — a net gain of 3 holders — while 40 added to existing stakes and 26 trimmed.

The largest buyer was Palo Alto Investors, adding an estimated $41.5M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $11.6M sold.

  • 98 institutional investors held Epizyme, Inc (EPZM) as of Q3 2015, up from 95 in Q2 2015.
  • Funds reported $465M of Epizyme, Inc stock for Q3 2015, down 44% quarter-over-quarter.
  • 16 funds opened new Epizyme, Inc positions in Q3 2015 and 13 closed out, a net change of +3 holders.
  • The largest Epizyme, Inc buyer in Q3 2015 was Palo Alto Investors, an estimated $41.5M added.
  • The largest Epizyme, Inc seller in Q3 2015 was Point72 Asset Management, an estimated $11.6M sold.

Based on aggregated 13F filings for Q3 2015.